To read the full story, subscribe or sign in.

Ascletis' $100M series B to advance HCV drugs to market in China

Jan. 4, 2017

SHANGHAI – The latest Chinese biopharma to receive a generous round of financing, Ascletis Pharmaceuticals Co. Ltd., of Hangzhou and Shaoxing, received $100 million from China-based venture capital firms.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for Dec. 13, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 13, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Keros stock wilts as it halts two dosing arms in hypertension study

BioWorld

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...